Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
Eur Urol
    February 2026
  1. CLARK PE
    Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
    >> Share

  2. NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
    Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
    Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
    >> Share

  3. LIU P, Chen J, Zhou J
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
    >> Share

  4. GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
    Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
    >> Share

  5. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
    Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].
    Eur Urol. 2026 Feb 17:S0302-2838(26)00063-1. doi: 10.1016/j.eururo.2026.
    >> Share

  6. PICHLER R, Subiela JD, Guerrero-Ramos F
    Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
    Eur Urol. 2026 Feb 4:S0302-2838(26)00054-0. doi: 10.1016/j.eururo.2026.
    >> Share

  7. GABRIEL PE, Xylinas E
    Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5.
    Eur Urol. 2026 Feb 3:S0302-2838(26)00030-8. doi: 10.1016/j.eururo.2026.
    >> Share

  8. BABJUK M
    Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial.
    Eur Urol. 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
    >> Share

  9. HAYNE D, Zhang AY, Thomas H, Krieger L, et al
    Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
    Eur Urol. 2026 Feb 2:S0302-2838(26)00015-1. doi: 10.1016/j.eururo.2026.
    >> Share

  10. TATEO V, Basile G, Giannatempo P, de Jong JJ, et al
    Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Feb 2:S0302-2838(26)00022-9. doi: 10.1016/j.eururo.2026.
    >> Share

  11. MYERS AA, Talwar R, Duan Z, Hensley P, et al
    Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guerin-unresponsive Carcinoma in Situ of the Bladder.
    Eur Urol. 2026;89:151-162.
    >> Share

    January 2026
  12. CABRERA C, Buisan O, Servian P
    Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
    Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
    >> Share

  13. KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
    Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
    Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
    >> Share

  14. GARMAN TS, Kates MR
    Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
    Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
    >> Share

  15. PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
    Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
    Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
    >> Share

  16. NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
    Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
    Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
    >> Share

  17. HERR H
    Re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol.
    Eur Urol. 2026 Jan 12:S0302-2838(25)04897-3. doi: 10.1016/j.eururo.2025.
    >> Share

  18. ROVIELLO G, Vascotto IA, Antonuzzo L
    Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Jan 12:S0302-2838(26)00008-4. doi: 10.1016/j.eururo.2026.
    >> Share

    December 2025
  19. SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
    Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
    Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
    >> Share

  20. FILHO AM, Briganti A, Jemal A, Bray F, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
    >> Share

  21. PANDOLFO SD, Bukavina L, Autorino R
    Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Dec 17:S0302-2838(25)04860-2. doi: 10.1016/j.eururo.2025.
    >> Share

  22. GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
    RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
    Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
    >> Share

  23. KHENE ZE, Bensalah K, Roupret M
    Artificial Intelligence for Risk Prediction in Non-muscle-invasive Bladder Cancer: From Complexity to Clinical Clarity.
    Eur Urol. 2025 Dec 3:S0302-2838(25)04831-6. doi: 10.1016/j.eururo.2025.
    >> Share

    November 2025
  24. HUANG H, Ma W, Zeng X, Liu B, et al
    Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.
    Eur Urol. 2025 Nov 4:S0302-2838(25)04768-2. doi: 10.1016/j.eururo.2025.
    >> Share

  25. CHU CE, Chen Z, Whiting K, Ostrovnaya I, et al
    Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
    Eur Urol. 2025;88:472-481.
    >> Share

  26. DE WIT R, Vaughn DJ, Fradet Y, Fong L, et al
    Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
    Eur Urol. 2025;88:462-471.
    >> Share

  27. HUSSAIN SA, Catto JWF
    Non-muscle-invasive Bladder Cancer: Many New Options, If You Can Afford Them.
    Eur Urol. 2025 Nov 1:S0302-2838(25)04771-2. doi: 10.1016/j.eururo.2025.
    >> Share

    October 2025
  28. MORTEZAVI A
    Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04777-3. doi: 10.1016/j.eururo.2025.
    >> Share

  29. PANEBIANCO V, Briganti A, Efstathiou JA, Galgano SJ, et al
    Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
    Eur Urol. 2025 Oct 31:S0302-2838(25)04769-4. doi: 10.1016/j.eururo.2025.
    >> Share

  30. DREYER T, Jensen JB
    Reply to Behzad Jazayeri, Xuefeng Wang, and Roger Li's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive B
    Eur Urol. 2025 Oct 23:S0302-2838(25)04739-6. doi: 10.1016/j.eururo.2025.
    >> Share

  31. JAZAYERI B, Wang X, Li R
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Oct 16:S0302-2838(25)04729-3. doi: 10.1016/j.eururo.2025.09.4168.
    >> Share

  32. FU MZ, Ghodoussipour S, Packiam VT
    The Future of Bladder Preservation for Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Oct 16:S0302-2838(25)04734-7. doi: 10.1016/j.eururo.2025.09.4173.
    >> Share

  33. BUISAN O, Servian P, Pedreno-Lopez S, Pages J, et al
    A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.
    Eur Urol. 2025 Oct 14:S0302-2838(25)00505-6. doi: 10.1016/j.eururo.2025.
    >> Share

  34. DANESHMAND S, Zaucha R, Catto JWF, Tran B, et al
    Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.
    Eur Urol. 2025 Oct 7:S0302-2838(25)04702-5. doi: 10.1016/j.eururo.2025.09.4152.
    >> Share

  35. KWONG JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, et al
    Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Can
    Eur Urol. 2025 Oct 7:S0302-2838(25)04688-3. doi: 10.1016/j.eururo.2025.09.4145.
    >> Share

  36. MEGHANI K, Yu Y, Frydenlund N, Li EZ, et al
    Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.
    Eur Urol. 2025 Oct 6:S0302-2838(25)04677-9. doi: 10.1016/j.eururo.2025.09.4138.
    >> Share

  37. BELLMUNT J, Powles T, Park SH, Voog E, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
    Eur Urol. 2025;88:331-338.
    >> Share

  38. GALSKY MD, van der Heijden MS, Powles T, Claps M, et al
    Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
    Eur Urol. 2025;88:325-330.
    >> Share

    September 2025
  39. SHI Z, Yang S, Yang Y
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Sep 27:S0302-2838(25)04682-2. doi: 10.1016/j.eururo.2025.
    >> Share

  40. ROVIELLO G, Antonuzzo L
    Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
    Eur Urol. 2025 Sep 27:S0302-2838(25)04695-0. doi: 10.1016/j.eururo.2025.
    >> Share

  41. DREYER T, Jensen JB
    Reply to Heidi Pharo, Hege Marie Vedeld, Rolf Wahlqvist, and Guro E. Lind's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
    Eur Urol. 2025 Sep 25:S0302-2838(25)04642-1. doi: 10.1016/j.eururo.2025.09.4129.
    >> Share

  42. PHARO H, Vedeld HM, Wahlqvist R, Lind GE, et al
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Sep 24:S0302-2838(25)04646-9. doi: 10.1016/j.eururo.2025.
    >> Share

  43. LI X, Wang X, Zhang G
    Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur
    Eur Urol. 2025 Sep 24:S0302-2838(25)04654-8. doi: 10.1016/j.eururo.2025.
    >> Share

  44. DING D, Qian L, Jin D, Zhou X, et al
    Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.
    Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025.
    >> Share

  45. ZUGMAN M, Carneiro A, Maluf FC
    Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic Subtypes of Bladder Cancer.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025.
    >> Share

  46. HECK MM, Lehmann J, Amiel T, Rubben H, et al
    Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
    Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025.
    >> Share

    August 2025
  47. RAYCHAUDHURI R, Khaki AR, Redman MW, Baker KK, et al
    Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.
    Eur Urol. 2025 Aug 4:S0302-2838(25)00391-4. doi: 10.1016/j.eururo.2025.
    >> Share

    July 2025
  48. GUO Y, Zhang W, Zhang J, Mao S, et al
    Re: Oncolytic Immunotherapy with Nivolumab in Muscle-invasive Bladder Cancer: A Phase 1b Trial.
    Eur Urol. 2025 Jul 28:S0302-2838(25)00406-3. doi: 10.1016/j.eururo.2025.
    >> Share

  49. ANKER JF, Yu M, Galsky MD
    Association Between Circulating Tumor DNA and Clinical Outcomes with Adjuvant Immune Checkpoint Blockade in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Cystectomy.
    Eur Urol. 2025 Jul 1:S0302-2838(25)00342-2. doi: 10.1016/j.eururo.2025.
    >> Share

    June 2025
  50. DREYER T, Jensen JB
    Reply to Xin Rui, Xiaoming Xu, and Bo Dai's Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Canc
    Eur Urol. 2025 Jun 24:S0302-2838(25)00348-3. doi: 10.1016/j.eururo.2025.
    >> Share

  51. CHANG SS, Launer B, Narayan V, Patil D, et al
    Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association
    Eur Urol. 2025 Jun 12:S0302-2838(25)00338-0. doi: 10.1016/j.eururo.2025.
    >> Share

  52. FU MZ, Ghodoussipour S, Packiam VT
    Re: Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results from Phase II Protocol NRG Oncology/RTOG 0926.
    Eur Urol. 2025 Jun 10:S0302-2838(25)00326-4. doi: 10.1016/j.eururo.2025.
    >> Share

  53. RUI X, Xu X, Dai B
    Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur
    Eur Urol. 2025 Jun 7:S0302-2838(25)00339-2. doi: 10.1016/j.eururo.2025.
    >> Share

    May 2025
  54. ST-LAURENT MP, Singh P, McConkey DJ, Lucia MS, et al
    Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 May 21:S0302-2838(25)00217-9. doi: 10.1016/j.eururo.2025.
    >> Share

  55. FANKHAUSER CD, Cathomas R
    Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results from the Prospective BladderPath Trial.
    Eur Urol. 2025 May 19:S0302-2838(25)00290-8. doi: 10.1016/j.eururo.2025.
    >> Share

  56. SCHOFIELD E, Catto JWF, Griffin J
    Subtypes and Sequencing in Bladder Cancer: Powering Personalised Treatment or Extraneous Information?
    Eur Urol. 2025 May 16:S0302-2838(25)00277-5. doi: 10.1016/j.eururo.2025.
    >> Share

  57. SUBIELA JD, Scilipoti P, Contieri R, Lobo N, et al
    Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical Cystectomy.
    Eur Urol. 2025 May 14:S0302-2838(25)00283-0. doi: 10.1016/j.eururo.2025.
    >> Share

  58. WARD DG, Bryan RT
    Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for Patients with Non-muscle-invasive Bladder Cancer?
    Eur Urol. 2025 May 10:S0302-2838(25)00268-4. doi: 10.1016/j.eururo.2025.
    >> Share

  59. ZAURITO P, Moschini M, Briganti A, Montorsi F, et al
    Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al. Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol 2024;42:4095-102.
    Eur Urol. 2025 May 3:S0302-2838(25)00250-7. doi: 10.1016/j.eururo.2025.
    >> Share

    April 2025
  60. ALFRED WITJES J
    Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be Adapted?
    Eur Urol. 2025 Apr 25:S0302-2838(25)00218-0. doi: 10.1016/j.eururo.2025.
    >> Share

  61. PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al
    Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini, and Andrea Salonia's Letter to the Editor re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and t
    Eur Urol. 2025 Apr 24:S0302-2838(25)00199-X. doi: 10.1016/j.eururo.2025.
    >> Share

  62. DREYER T, Brandt S, Fabrin K, Azawi N, et al
    Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial.
    Eur Urol. 2025 Apr 24:S0302-2838(25)00191-5. doi: 10.1016/j.eururo.2025.
    >> Share

  63. GUPTA S, Hensley PJ, Li R, Choudhury A, et al
    Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    Eur Urol. 2025 Apr 22:S0302-2838(25)00189-7. doi: 10.1016/j.eururo.2025.
    >> Share

  64. GHODOUSSIPOUR S, Bivalacqua T, Bryan RT, Li R, et al
    A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Apr 18:S0302-2838(25)00123-X. doi: 10.1016/j.eururo.2025.
    >> Share

  65. KOSHKIN VS, Danchaivijitr P, Bae WK, Semenov A, et al
    Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
    Eur Urol. 2025;87:390-395.
    >> Share

    March 2025
  66. VAN DER HEIJDEN AG, Bruins HM, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00138-1. doi: 10.1016/j.eururo.2025.
    >> Share

  67. VAN DOEVEREN T, Aben KKH, van Leeuwen PJ, Boormans JL, et al
    Reply to Alexandra Masson-Lecomte. Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.004.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00151-4. doi: 10.1016/j.eururo.2025.
    >> Share

  68. MONTORSI F, Rosiello G, Gandaglia G, Salonia A, et al
    Re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol 2024;86:531-49.
    Eur Urol. 2025 Mar 11:S0302-2838(25)00125-3. doi: 10.1016/j.eururo.2025.
    >> Share

  69. GONTERO P, Soria F
    Reply to Francesco Montorsi, Giuseppe Rosiello, Giorgio Gandaglia, Andrea Salonia and Alberto Briganti's Letter to the Editor re: Paolo Gontero, Alison Birtle, Otakar Capoun, et al. European Association of Urology Guidelines on Non-muscle-invasive Bla
    Eur Urol. 2025 Mar 11:S0302-2838(25)00140-X. doi: 10.1016/j.eururo.2025.
    >> Share

  70. FLAMMIA RS, Leonardo C, Simone G
    Re: Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
    Eur Urol. 2025 Mar 10:S0302-2838(25)00132-0. doi: 10.1016/j.eururo.2025.
    >> Share

  71. YU M, Goel A, Tura B, Whalley CM, et al
    Towards Epigenetic-based Subtyping of Bladder Cancer: DNA Methylation Predicts Molecular Subtypes of Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Mar 7:S0302-2838(25)00126-5. doi: 10.1016/j.eururo.2025.
    >> Share

    February 2025
  72. MONTORSI F, Rosiello G, Scilipoti P, Moschini M, et al
    Re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the Amer
    Eur Urol. 2025 Feb 27:S0302-2838(25)00120-4. doi: 10.1016/j.eururo.2025.
    >> Share

  73. ECKE TH, Le Calvez-Kelm F, van Poppel H
    Why We Need More Attention on Bladder Cancer: Establishing Policy Recommendations for Health Care Professionals and Politicians.
    Eur Urol. 2025 Feb 19:S0302-2838(25)00095-8. doi: 10.1016/j.eururo.2025.
    >> Share

  74. HURLE R, Bernardini B, Contieri R, Lazzeri M, et al
    Re: Characterizing Psychological Resources and Resilience in Patients with Bladder Cancer: Associations with Frailty and Quality of Life.
    Eur Urol. 2025 Feb 3:S0302-2838(25)00022-3. doi: 10.1016/j.eururo.2025.
    >> Share

  75. LI R, Linscott J, Catto JWF, Daneshmand S, et al
    FGFR Inhibition in Urothelial Carcinoma.
    Eur Urol. 2025;87:110-122.
    >> Share

    January 2025
  76. STENZL A
    The Cost of Bladder Cancer: What Can Be Done?
    Eur Urol. 2025 Jan 28:S0302-2838(25)00017-X. doi: 10.1016/j.eururo.2025.
    >> Share

  77. RAGGI D, Chakrabarti D, Green H, Huddart RA, et al
    Re: Standard or Extended Lymphadenectomy for Muscle-invasive Bladder Cancer.
    Eur Urol. 2025 Jan 27:S0302-2838(25)00020-X. doi: 10.1016/j.eururo.2025.
    >> Share

  78. DAVIS LE, Calaway A, Shoag J
    Re: Robert Huddart, Shaista Hafeez, Clare Griffin, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomized Controlled Trial. Eur Urol 2025;87:60-70.
    Eur Urol. 2025 Jan 21:S0302-2838(25)00007-7. doi: 10.1016/j.eururo.2024.
    >> Share

  79. MASSON-LECOMTE A
    Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity.
    Eur Urol. 2025 Jan 21:S0302-2838(25)00015-6. doi: 10.1016/j.eururo.2025.
    >> Share

  80. FRAGKOULIS C, Bamias A, Gavalas N, Tzannis K, et al
    Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
    Eur Urol. 2025 Jan 17:S0302-2838(24)02785-4. doi: 10.1016/j.eururo.2024.
    >> Share

  81. AFFERI L, Cimadamore A, Gallioli A, Pradere B, et al
    Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
    Eur Urol. 2025;87:1-4.
    >> Share

    December 2024
  82. SCILIPOTI P, Moschini M, Li R, Lerner SP, et al
    The Financial Burden of Localized and Metastatic Bladder Cancer.
    Eur Urol. 2024 Dec 26:S0302-2838(24)02744-1. doi: 10.1016/j.eururo.2024.
    >> Share

    October 2024
  83. MYERS AA, Kamat AM
    Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li's Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gueri
    Eur Urol. 2024 Oct 15:S0302-2838(24)02642-3. doi: 10.1016/j.eururo.2024.
    >> Share

  84. GUSKE C, Jazayeri SB, Li R
    Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027.
    Eur Urol. 2024 Oct 14:S0302-2838(24)02638-1. doi: 10.1016/j.eururo.2024.
    >> Share

  85. SHARIAT SF
    Navigating the Challenges of BCG-Unresponsive Non-muscle-invasive Bladder Cancer: Insights and Future Directions.
    Eur Urol. 2024 Oct 7:S0302-2838(24)02620-4. doi: 10.1016/j.eururo.2024.
    >> Share

  86. ZHOU W, Zu X, Hu J
    Re: Srikala S. Sridhar, Thomas Powles, Miguel. A. Climent Duran, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. Eur Ur
    Eur Urol. 2024;86:e96.
    >> Share

  87. NORDENTOFT I, Lindskrog SV, Birkenkamp-Demtroder K, Gonzalez S, et al
    Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Eur Urol. 2024;86:301-311.
    >> Share

  88. MUNOZ-LOPEZ C, Rathi N, Campbell SC
    Predicting Renal Function following Nephroureterectomy can Impact Timing of Systemic Chemotherapy.
    Eur Urol. 2024;86:378-379.
    >> Share

  89. GAKIS G
    Re: Immune Contexture Changes Following Blue Light Cystoscopy with Hexaminolevulinate in Bladder Cancer.
    Eur Urol. 2024 Oct 1:S0302-2838(24)02619-8. doi: 10.1016/j.eururo.2024.
    >> Share

    September 2024
  90. HUDDART R, Hafeez S, Griffin C, Choudhury A, et al
    Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.
    Eur Urol. 2024 Sep 24:S0302-2838(24)02596-X. doi: 10.1016/j.eururo.2024.
    >> Share

  91. PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al
    The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02606-X. doi: 10.1016/j.eururo.2024.
    >> Share

  92. CATALANO M, Santoni M, Roviello G
    Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Eur Urol. 2024;86:283.
    >> Share

  93. CHEN DC, AlSaffar H, Graefen H, Perera S, et al
    Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Eur Urol. 2024;86:282-283.
    >> Share

  94. KLUMPER N, Vera-Badillo FE, Eckstein M, Hadaschik B, et al
    Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Eur Urol. 2024;86:280-281.
    >> Share

    August 2024
  95. BEIJERT IJ, Hagberg O, Gardmark T, Holmberg L, et al
    The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Aug 28:S0302-2838(24)02528-4. doi: 10.1016/j.eururo.2024.
    >> Share

  96. PLAGE H, Dressler FF, Fendler A
    Patient-derived Models: A Promising Frontier in Testing the Efficacy of Drugs for Bladder Cancer.
    Eur Urol. 2024 Aug 25:S0302-2838(24)02556-9. doi: 10.1016/j.eururo.2024.
    >> Share

  97. LI R, Hensley PJ, Gupta S, Al-Ahmadie H, et al
    Bladder-sparing Therapy for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.
    Eur Urol. 2024 Aug 24:S0302-2838(24)02516-8. doi: 10.1016/j.eururo.2024.
    >> Share

  98. COLOMBEL M
    Re: Predicting Non-muscle Invasive Bladder Cancer Outcomes Using Artificial Intelligence: A Systematic Review Using APPRAISE-AI.
    Eur Urol. 2024 Aug 21:S0302-2838(24)02521-1. doi: 10.1016/j.eururo.2024.
    >> Share

  99. BROOKMAN-MAY SD, Kamat AM, May M
    Re: Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Aug 19:S0302-2838(24)02553-3. doi: 10.1016/j.eururo.2024.
    >> Share

  100. GONTERO P, Birtle A, Capoun O, Comperat E, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02514-4. doi: 10.1016/j.eururo.2024.
    >> Share

  101. MERRILL NM, Kaffenberger SD, Bao L, Vandecan N, et al
    Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02408-4. doi: 10.1016/j.eururo.2024.
    >> Share

  102. COMPERAT E, Wasinger G, Klager J
    Re: Metastasis and Recurrence Patterns in the Molecular Subtypes of Urothelial Bladder Cancer.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02518-1. doi: 10.1016/j.eururo.2024.
    >> Share

  103. DE JONG JJ, Lotan Y, Boormans JL
    Re: EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
    Eur Urol. 2024 Aug 10:S0302-2838(24)02511-9. doi: 10.1016/j.eururo.2024.
    >> Share

  104. YUEN-CHUN TEOH J, Cheng CH, Tsang CF, Kai-Man Li J, et al
    Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial.
    Eur Urol. 2024;86:103-111.
    >> Share

  105. BECCIA V, Pinterpe G, Iacovelli R
    Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:1
    Eur Urol. 2024;86:e44-e45.
    >> Share

  106. DRAKE MJ, Birder LA
    Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma.
    Eur Urol. 2024;86:183-184.
    >> Share

  107. MANCON S, Ofner H, D'Andrea D
    Re: Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-year Outcomes from a Randomized Controlled Trial.
    Eur Urol. 2024;86:186-187.
    >> Share

    July 2024
  108. PLIMACK ER, Tangen C, Plets M, Kokate R, et al
    Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.
    Eur Urol. 2024 Jul 12:S0302-2838(24)02453-9. doi: 10.1016/j.eururo.2024.
    >> Share

  109. DEBATIN NF, Bady E, Mandelkow T, Huang Z, et al
    Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer.
    Eur Urol. 2024;86:42-51.
    >> Share

    June 2024
  110. MYERS AA, Tan WS, Grajales V, Hwang H, et al
    Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guerin Have an Effect?
    Eur Urol. 2024 Jun 14:S0302-2838(24)02409-6. doi: 10.1016/j.eururo.2024.
    >> Share

  111. TILGENER C, Bedke J
    Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2024;85:591-592.
    >> Share

  112. ROSENBERG JE, Mamtani R, Sonpavde GP, Loriot Y, et al
    Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
    Eur Urol. 2024;85:574-585.
    >> Share

    May 2024
  113. BABJUK M
    Can an En Bloc Technique Improve Outcomes of Endoscopic Surgery for Non-muscle-invasive Bladder Cancer?
    Eur Urol. 2024 May 25:S0302-2838(24)02382-0. doi: 10.1016/j.eururo.2024.
    >> Share

  114. ABSOLOM K, Rogers Z, Catto JWF, Bottomley S, et al
    Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer.
    Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
    >> Share

  115. THALMANN GN
    Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Surgery: All Is in the Eye of the Beholder.
    Eur Urol. 2024;85:431-432.
    >> Share

  116. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial.
    Eur Urol. 2024;85:422-430.
    >> Share

    April 2024
  117. ST-LAURENT MP, Black PC
    Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
    Eur Urol. 2024 Apr 12:S0302-2838(24)02259-0. doi: 10.1016/j.eururo.2024.
    >> Share

  118. BABJUK M
    Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Apr 9:S0302-2838(24)02262-0. doi: 10.1016/j.eururo.2024.
    >> Share

  119. LIEDBERG F, Bobjer J
    Re: Longer is Better for Endoscopic Follow-up of Upper Tract Urothelial Carcinoma After Ureteroscopic Treatment: An Evaluation Spanning 10 Years of Data.
    Eur Urol. 2024;85:392.
    >> Share

  120. LINSCOTT JA, Meeks JJ, Dyrskjot L, Li R, et al
    The Elusive Horizon: Biomarkers in Urothelial Carcinoma.
    Eur Urol. 2024;85:317-319.
    >> Share

  121. DAHM P, Ergun O, Sathianathen N
    Re: Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, et al. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Contr
    Eur Urol. 2024;85:e116.
    >> Share

  122. PIRAMIDE F, Turri F, Amparore D, Fallara G, et al
    Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes.
    Eur Urol. 2024;85:348-360.
    >> Share

  123. COX A, Klumper N, Stein J, Sikic D, et al
    Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.
    Eur Urol. 2024;85:328-332.
    >> Share

    March 2024
  124. DUQUESNE I, de la Taille A
    Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
    >> Share

  125. ZHOU Y, D'Andrea VD, Shanmugam SP, Stelter I, et al
    Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
    Eur Urol. 2024 Mar 23:S0302-2838(24)02231-0. doi: 10.1016/j.eururo.2024.
    >> Share

  126. ALFRED WITJES J, Bruins HM, Carrion A, Cathomas R, et al
    Corrigendum to "European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines" [Eur. Urol. 85 (2024) 17-31].
    Eur Urol. 2024 Mar 15:S0302-2838(24)02194-8. doi: 10.1016/j.eururo.2024.
    >> Share

  127. GUPTA S, Necchi A
    LEAP-011 in Urothelial Cancer. Unraveling the Puzzle: Combination or Cohort?
    Eur Urol. 2024;85:239-241.
    >> Share

  128. HUELSTER HL, Gould B, Schiftan EA, Camperlengo L, et al
    Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma.
    Eur Urol. 2024;85:283-292.
    >> Share

  129. MATSUBARA N, de Wit R, Balar AV, Siefker-Radtke AO, et al
    Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Eur Urol. 2024;85:229-238.
    >> Share

  130. HEER R, Tan WS, Gravestock P, Vadiveloo T, et al
    Reply to Arnulf Stenzl, Morgan Roupret, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193-4.
    Eur Urol. 2024;85:309-312.
    >> Share

  131. CAVILLON A, Pouessel D, Houede N, Mathevet F, et al
    Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials.
    Eur Urol. 2024;85:293-300.
    >> Share

    February 2024
  132. VAN DER KWAST TH, Bubendorf L, Cheng L
    International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations.
    Eur Urol. 2024 Feb 26:S0302-2838(24)00080-0. doi: 10.1016/j.eururo.2024.
    >> Share

  133. MOSCHINI M, Necchi A, Montorsi F
    Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Eur Urol. 2024 Feb 17:S0302-2838(24)00068-X. doi: 10.1016/j.eururo.2023.
    >> Share

  134. SHARIAT SF, Laukhtina E
    Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S, Izadmehr S, et al. Nat Med 2023;29:2825-34.
    Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
    >> Share

  135. NAOUN N, Loriot Y
    Towards Tailored Adjuvant Therapy in Bladder Urothelial Carcinoma: How Should We Fit Each Size?
    Eur Urol. 2024;85:123-124.
    >> Share

  136. SRIDHAR SS, Powles T, Climent Duran MA, Park SH, et al
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Eur Urol. 2024;85:154-163.
    >> Share

  137. POWLES T, Assaf ZJ, Degaonkar V, Grivas P, et al
    Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Eur Urol. 2024;85:114-122.
    >> Share

    January 2024
  138. BINHUMAID FS, Goel A, Gordon NS, Abbotts B, et al
    Circulating Tumour Dna Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients.
    Eur Urol. 2024 Jan 31:S0302-2838(24)00017-4. doi: 10.1016/j.eururo.2024.
    >> Share

  139. KIM SK, Byun YJ, Park SH, Piao XM, et al
    A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Jan 11:S0302-2838(24)00001-0. doi: 10.1016/j.eururo.2024.
    >> Share

  140. PEDERZOLI F, Riba M, Venegoni C, Marandino L, et al
    Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Jan 5:S0302-2838(23)03341-9. doi: 10.1016/j.eururo.2023.
    >> Share

  141. XIE Q, Shen D
    Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
    Eur Urol. 2024;85:e17-e18.
    >> Share

  142. PRASAD RAI B, Violette PD, Imran Omar M
    Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with H
    Eur Urol. 2024;85:e15-e16.
    >> Share

    December 2023
  143. YOLMO P, Siemens DR, Koti M
    Predicting Response in TIME and Space: Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 23:S0302-2838(23)03296-7. doi: 10.1016/j.eururo.2023.
    >> Share

  144. BECKABIR W, Wobker SE, Damrauer JS, Midkiff B, et al
    Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
    >> Share

  145. FENG YN, Xie GY, Xiao L
    Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95-108.
    Eur Urol. 2023;84:e145.
    >> Share

  146. PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
    Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Blad
    Eur Urol. 2023;84:e154.
    >> Share

  147. LI DX, Feng DC, Deng S
    Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-gui
    Eur Urol. 2023;84:e152-e153.
    >> Share

    November 2023
  148. KLUMPER N, Eckstein M, Holzel M, Herrmann K, et al
    Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT.
    Eur Urol. 2023;84:514-515.
    >> Share

  149. MEEKS JJ, Black PC, Galsky M, Grivas P, et al
    Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
    Eur Urol. 2023;84:473-483.
    >> Share

  150. MARTINI A, Falagario UG, Russo A, Mertens LS, et al
    Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
    Eur Urol. 2023;84:484-490.
    >> Share

    October 2023
  151. WANG Z, Zeng S, Xu C
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
    >> Share

  152. HENSLEY PJ, Choudhury A, Khaki AR, Grivas P, et al
    The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
    >> Share

  153. SEISEN T, Roupret M, Trinh QD, Bellmunt J, et al
    Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J
    Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
    >> Share

  154. SWINTON M, Hoskin P, Choudhury A
    Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alterna
    Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
    >> Share

  155. ALFRED WITJES J, Max Bruins H, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
    Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
    >> Share

  156. KULKARNI GS, Wettstein MS
    SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
    >> Share

  157. KHETRAPAL P, Wong JKL, Tan WP, Rupasinghe T, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials.
    Eur Urol. 2023;84:393-405.
    >> Share

    September 2023
  158. FENG M, Matoso A, Epstein G, Fong M, et al
    Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
    Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
    >> Share

  159. STRANDGAARD T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, et al
    Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer.
    Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
    >> Share

  160. INAMURA K
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
    >> Share

  161. ZLOTTA AR, Lajkosz K, Efstathiou JA
    Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institut
    Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
    >> Share

    August 2023
  162. SEISEN T, Roupret M, Blanchard P
    Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
    >> Share

  163. BLACK PC, Tangen CM, Singh P, McConkey DJ, et al
    Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
    >> Share

  164. SUSSMAN J, Konety B, Ahmadi H
    Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
    Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
    >> Share

    July 2023
  165. BASILE G, Audenet F, Seisen T, Pradere B, et al
    The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials.
    Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
    >> Share

  166. CIGLIOLA A, Mercinelli C, Patane D, Raggi D, et al
    Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
    Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
    >> Share

  167. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
    >> Share

  168. LABAKI C, Saad E, Choueiri TK, Bellmunt J, et al
    Oligometastatic Bladder Cancer: Defining a Novel Entity.
    Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
    >> Share

  169. GRIVAS P, Park SH, Voog E, Caserta C, et al
    Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Eur Urol. 2023;84:95-108.
    >> Share

  170. ROUPRET M, Seisen T, Birtle AJ, Capoun O, et al
    European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
    Eur Urol. 2023;84:49-64.
    >> Share

  171. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
    Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
    Eur Urol. 2023;84:117-126.
    >> Share

  172. KOTI M, Robert Siemens D
    A Step Closer to Predicting Progression After Bacillus Calmette-Guerin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
    >> Share

    June 2023
  173. FENG M, Matoso A, Epstein G, Fong M, et al
    Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
    >> Share

  174. GROENEVELD CS, Sanchez-Quiles V, Dufour F, Shi M, et al
    Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
    >> Share

  175. BORREGALES LD, Venkat S, Posada Calderon L, Lewicki P, et al
    A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
    >> Share

  176. O'CALLAGHAN M
    Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial.
    Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
    >> Share

  177. MOSCHINI M, Montorsi F
    Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors.
    Eur Urol. 2023;83:582.
    >> Share

  178. LAUKHTINA E, Shariat SF
    Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
    >> Share

    May 2023
  179. MAKAROFF LE, Filicevas A, Boldon S, Hensley P, et al
    Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
    Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
    >> Share

  180. BAMIAS A, Stenzl A, Brown SL, Albiges L, et al
    Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
    Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
    >> Share

  181. KOUTROS S, Kiemeney LA, Pal Choudhury P, Milne RL, et al
    Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
    Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
    >> Share

  182. JUBBER I, Ong S, Bukavina L, Black PC, et al
    Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
    Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
    >> Share

  183. GALSKY MD, Bajorin DF, Witjes JA, Gschwend JE, et al
    Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
    Eur Urol. 2023;83:432-440.
    >> Share

    April 2023
  184. LENFANT L, Pinar U, Roupret M, Seisen T, et al
    Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
    Eur Urol. 2023 Apr 17:S0302-2838(23)02714-8. doi: 10.1016/j.eururo.2023.
    >> Share

  185. MOLINA GE, Schwartz B, Srinivas S, Shah S, et al
    In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
    Eur Urol. 2023;83:377-378.
    >> Share

  186. BERGEROT CD, Gupta S
    Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
    Eur Urol. 2023;83:329-330.
    >> Share

  187. GRIVAS P, Kopyltsov E, Su PJ, Parnis FX, et al
    Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Eur Urol. 2023;83:320-328.
    >> Share

    March 2023
  188. MOSCHINI M, Salonia A, Briganti A, Montorsi F, et al
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    Eur Urol. 2023 Mar 24:S0302-2838(23)02649-0. doi: 10.1016/j.eururo.2023.
    >> Share

  189. CHENG C, Hu J, Chen J
    Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
    Eur Urol. 2023 Mar 24:S0302-2838(23)02653-2. doi: 10.1016/j.eururo.2023.
    >> Share

  190. CERRATO C, Roupret M, Mir MC
    Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
    Eur Urol. 2023 Mar 23:S0302-2838(23)02643-X. doi: 10.1016/j.eururo.2023.
    >> Share

  191. LENFANT L, Pinar U, Roupret M, Seisen T, et al
    First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?
    Eur Urol. 2023 Mar 18:S0302-2838(23)02637-4. doi: 10.1016/j.eururo.2023.
    >> Share

  192. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
    Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
    Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
    >> Share

  193. MAITRE P, Sangar V, Choudhury A
    ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
    >> Share

  194. STENZL A, Roupret M, Witjes JA, Gontero P, et al
    High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
    Eur Urol. 2023;83:193-194.
    >> Share

    February 2023
  195. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
    Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016